Celsius Therapeutics
acquired by AbbVieCambridge, US · Founded 2017 · Delaware corporation · 2 known investors
Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine. Acquired by AbbVie Inc. in June 2024.
Founders & leadership
TK
Tariq KassumExecutive
MB
Michael BorettiNamed on SEC filing
CL
Christoph LengauerNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$48M disclosed across 1 round · 2018
▶$48MraisedOct 2019 · 6 investors · Other Health CareRule 506(b)
▶$48MraisedOct 2019 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael BorettiExecutive Officer
- Tariq KassumExecutive Officer, Director
- Christoph LengauerExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $48M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Celsius Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Celsius Therapeutics do?
- Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine. Acquired by AbbVie Inc. in June 2024.
- Who are Celsius Therapeutics's investors?
- Celsius Therapeutics's investors include Catalio Capital Management, LP, Fast Track Initiative.
- How much funding has Celsius Therapeutics raised?
- Celsius Therapeutics has disclosed $48M raised across 1 round.
- Who acquired Celsius Therapeutics?
- Celsius Therapeutics was acquired by AbbVie.
- Where is Celsius Therapeutics headquartered?
- Celsius Therapeutics is headquartered in Cambridge, US.